A phase I/II study of RAD001 [everolimus] in advanced hepatocellular carcinoma

Trial Profile

A phase I/II study of RAD001 [everolimus] in advanced hepatocellular carcinoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Feb 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Feb 2017 Last checked against ClinicalTrials.gov record.
    • 17 Mar 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 10 Sep 2007 Status changed to initiated to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top